Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05940402 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
A Phase 1 study of Renal Impairment, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 5
- Study locations
NCT05940402 is a Phase 1 study of Renal Impairment that has completed, run by AbbVie. The registered enrollment target is 58 participants, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (76% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT05940402, a Phase 1 study of Renal Impairment, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal impairment relative to matched participants with normal renal function.
Conditions Studied
Interventions
- DRUG Emraclidine
Study Locations (5)
Florida
- Miami, Florida - Miami
- Miami, Florida - Miami
- Orlando, Florida - Orlando
California
- Tustin, California - Tustin
Tennessee
- Knoxville, Tennessee - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2024-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05940402
The ClinicalTrials.gov registry entry for NCT05940402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (76% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Emraclidine is the first listed.
NCT05940402 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05940402 about?
NCT05940402 is a clinical study titled "A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function". The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal impairment relative to matched participants with normal renal function.
What is the current status of trial NCT05940402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2023-07-24. Estimated completion is 2024-12-19.
What conditions does trial NCT05940402 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT05940402?
The interventions under investigation include: Emraclidine (DRUG).
Who is sponsoring clinical trial NCT05940402?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05940402 being conducted?
This trial has 5 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.